Wennerberg et al. reported that an anticancer chemotherapeutic agent, doxorubicin, augmented the activity of NK cells by modulating the signaling TRAIL receptor [40]; the activity of TRAIL is regulated by cancer-related genes and miRNAs [20]. This evidence concerns the gene TNFSF10 and cancer.